Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Kushal Kandhari

Concepts (76)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Corneal Injuries
4
2024
42
1.340
Why?
Arsenicals
1
2023
28
0.790
Why?
Mustard Gas
4
2025
77
0.760
Why?
Chemical Warfare Agents
4
2025
89
0.750
Why?
Rabbits
5
2025
653
0.370
Why?
Dexamethasone
4
2025
365
0.310
Why?
Breast Neoplasms
1
2023
2393
0.310
Why?
Irritants
2
2024
42
0.250
Why?
Procollagen-Proline Dioxygenase
1
2026
27
0.240
Why?
Collagen Type I
1
2026
143
0.220
Why?
Smoke
1
2026
148
0.220
Why?
Limbus Corneae
1
2025
8
0.220
Why?
Apoptosis
2
2024
2443
0.220
Why?
Cigarette Smoking
1
2026
102
0.220
Why?
G2 Phase Cell Cycle Checkpoints
1
2024
44
0.210
Why?
Cyclin-Dependent Kinase Inhibitor p27
1
2024
64
0.210
Why?
Flavonols
1
2024
27
0.200
Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2024
106
0.200
Why?
Flavonoids
1
2024
85
0.200
Why?
Matrix Metalloproteinases
1
2024
95
0.200
Why?
Unfolded Protein Response
1
2023
58
0.200
Why?
Collagen
1
2026
457
0.200
Why?
Receptor-Interacting Protein Serine-Threonine Kinases
1
2023
14
0.190
Why?
Flavones
1
2023
11
0.190
Why?
Protein Processing, Post-Translational
1
2026
473
0.190
Why?
Acetylcysteine
1
2023
139
0.190
Why?
Nuclear Pore Complex Proteins
1
2023
40
0.190
Why?
Neoplastic Stem Cells
1
2026
409
0.180
Why?
Epithelial-Mesenchymal Transition
1
2024
220
0.180
Why?
Cell Death
1
2023
382
0.180
Why?
Anti-Inflammatory Agents
1
2025
478
0.170
Why?
Xenograft Model Antitumor Assays
1
2024
936
0.160
Why?
MAP Kinase Signaling System
1
2023
308
0.160
Why?
Stem Cells
1
2025
630
0.160
Why?
Oxidative Stress
2
2025
1359
0.160
Why?
Reactive Oxygen Species
1
2023
611
0.150
Why?
Antioxidants
1
2023
550
0.150
Why?
RNA-Binding Proteins
1
2023
447
0.140
Why?
Animals
10
2026
38097
0.140
Why?
Cornea
3
2024
154
0.140
Why?
Cell Line, Tumor
2
2024
3551
0.140
Why?
Pulmonary Disease, Chronic Obstructive
1
2024
920
0.120
Why?
Disease Progression
1
2024
2865
0.120
Why?
Adenocarcinoma
1
2022
926
0.110
Why?
Prostatic Neoplasms
1
2022
981
0.110
Why?
Lung Neoplasms
1
2026
2667
0.090
Why?
Humans
8
2026
145763
0.070
Why?
Prolyl Hydroxylases
1
2026
6
0.060
Why?
Hydroxylation
1
2026
47
0.060
Why?
Matrix Metalloproteinase Inhibitors
1
2024
17
0.050
Why?
Mechlorethamine
1
2024
52
0.050
Why?
Caspases
1
2024
233
0.050
Why?
Actin Cytoskeleton
1
2024
103
0.050
Why?
Mice
3
2026
18355
0.050
Why?
Mice, Nude
1
2024
680
0.050
Why?
Transcriptional Regulator ERG
1
2022
14
0.050
Why?
Tumor Microenvironment
1
2026
735
0.040
Why?
Chromatography, Liquid
1
2024
450
0.040
Why?
Ligands
1
2024
668
0.040
Why?
Signal Transduction
2
2026
5223
0.040
Why?
Actins
1
2024
426
0.040
Why?
Serine Endopeptidases
1
2022
129
0.040
Why?
DNA Damage
1
2024
437
0.040
Why?
Prostate
1
2022
159
0.040
Why?
Inflammation Mediators
1
2024
507
0.040
Why?
Tandem Mass Spectrometry
1
2024
572
0.040
Why?
Fibroblasts
1
2026
1027
0.040
Why?
Carcinogenesis
1
2022
228
0.040
Why?
Oncogene Proteins, Fusion
1
2022
212
0.040
Why?
Head and Neck Neoplasms
1
2024
561
0.040
Why?
Mice, Knockout
1
2026
3130
0.040
Why?
Proteomics
1
2024
1188
0.030
Why?
Cell Proliferation
1
2024
2514
0.030
Why?
Female
1
2023
79035
0.030
Why?
Inflammation
1
2025
2883
0.020
Why?
Male
2
2025
73003
0.010
Why?
Kandhari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)